The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Human Immune Globulin Intravenous Market Research Report 2025
Synopsis
Immune globulin (Ig) short-term protection against hepatitis A and measles
The global Human Immune Globulin Intravenous market was valued at US$ 13360 million in 2023 and is anticipated to reach US$ 21770 million by 2030, witnessing a CAGR of 7.1% during the forecast period 2024-2030.
The market growth can be attributed to several factors. Firstly, the increasing prevalence of bleeding disorders, driven by factors such as genetic predisposition, aging population, and improved diagnostic capabilities, has fueled the demand for coagulation factor products. Additionally, advancements in recombinant DNA technology and biotechnology have enabled the development of highly purified and more effective coagulation factor concentrates, offering improved treatment options for patients.Furthermore, the rising awareness about bleeding disorders and the availability of comprehensive treatment programs have contributed to increased diagnosis rates and access to coagulation factor therapies. Improved reimbursement policies and healthcare infrastructure have also played a role in expanding market reach.
This report aims to provide a comprehensive presentation of the global market for Human Immune Globulin Intravenous, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Immune Globulin Intravenous.
Report Scope
The Human Immune Globulin Intravenous market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Immune Globulin Intravenous market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Immune Globulin Intravenous manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
Grifols
CSL
Octapharma
Biotest
Kedrion
Hualan Bio
CNBG
Shanghai RAAS
CBPO
LFB Group
BPL
Sichuan Yuanda Shuyang
Segment by Type
IVIg Liquid
IVIg Powder
Segment by Application
Immunodeficiency
Autoimmune Disease
Acute Infection
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Immune Globulin Intravenous manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Immune Globulin Intravenous in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Immune globulin (Ig) short-term protection against hepatitis A and measles
The global Human Immune Globulin Intravenous market was valued at US$ 13360 million in 2023 and is anticipated to reach US$ 21770 million by 2030, witnessing a CAGR of 7.1% during the forecast period 2024-2030.
The market growth can be attributed to several factors. Firstly, the increasing prevalence of bleeding disorders, driven by factors such as genetic predisposition, aging population, and improved diagnostic capabilities, has fueled the demand for coagulation factor products. Additionally, advancements in recombinant DNA technology and biotechnology have enabled the development of highly purified and more effective coagulation factor concentrates, offering improved treatment options for patients.Furthermore, the rising awareness about bleeding disorders and the availability of comprehensive treatment programs have contributed to increased diagnosis rates and access to coagulation factor therapies. Improved reimbursement policies and healthcare infrastructure have also played a role in expanding market reach.
This report aims to provide a comprehensive presentation of the global market for Human Immune Globulin Intravenous, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Immune Globulin Intravenous.
Report Scope
The Human Immune Globulin Intravenous market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Immune Globulin Intravenous market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Immune Globulin Intravenous manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
Grifols
CSL
Octapharma
Biotest
Kedrion
Hualan Bio
CNBG
Shanghai RAAS
CBPO
LFB Group
BPL
Sichuan Yuanda Shuyang
Segment by Type
IVIg Liquid
IVIg Powder
Segment by Application
Immunodeficiency
Autoimmune Disease
Acute Infection
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Immune Globulin Intravenous manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Immune Globulin Intravenous in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Human Immune Globulin Intravenous Market Overview
1.1 Product Overview and Scope of Human Immune Globulin Intravenous
1.2 Human Immune Globulin Intravenous Segment by Type
1.2.1 Global Human Immune Globulin Intravenous Market Value Comparison by Type (2024-2030)
1.2.2 IVIg Liquid
1.2.3 IVIg Powder
1.3 Human Immune Globulin Intravenous Segment by Application
1.3.1 Global Human Immune Globulin Intravenous Market Value by Application: (2024-2030)
1.3.2 Immunodeficiency
1.3.3 Autoimmune Disease
1.3.4 Acute Infection
1.4 Global Human Immune Globulin Intravenous Market Size Estimates and Forecasts
1.4.1 Global Human Immune Globulin Intravenous Revenue 2019-2030
1.4.2 Global Human Immune Globulin Intravenous Sales 2019-2030
1.4.3 Global Human Immune Globulin Intravenous Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Human Immune Globulin Intravenous Market Competition by Manufacturers
2.1 Global Human Immune Globulin Intravenous Sales Market Share by Manufacturers (2019-2024)
2.2 Global Human Immune Globulin Intravenous Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Human Immune Globulin Intravenous Average Price by Manufacturers (2019-2024)
2.4 Global Human Immune Globulin Intravenous Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Immune Globulin Intravenous, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Immune Globulin Intravenous, Product Type & Application
2.7 Human Immune Globulin Intravenous Market Competitive Situation and Trends
2.7.1 Human Immune Globulin Intravenous Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Human Immune Globulin Intravenous Players Market Share by Revenue
2.7.3 Global Human Immune Globulin Intravenous Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Human Immune Globulin Intravenous Retrospective Market Scenario by Region
3.1 Global Human Immune Globulin Intravenous Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Human Immune Globulin Intravenous Global Human Immune Globulin Intravenous Sales by Region: 2019-2030
3.2.1 Global Human Immune Globulin Intravenous Sales by Region: 2019-2024
3.2.2 Global Human Immune Globulin Intravenous Sales by Region: 2025-2030
3.3 Global Human Immune Globulin Intravenous Global Human Immune Globulin Intravenous Revenue by Region: 2019-2030
3.3.1 Global Human Immune Globulin Intravenous Revenue by Region: 2019-2024
3.3.2 Global Human Immune Globulin Intravenous Revenue by Region: 2025-2030
3.4 North America Human Immune Globulin Intravenous Market Facts & Figures by Country
3.4.1 North America Human Immune Globulin Intravenous Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Human Immune Globulin Intravenous Sales by Country (2019-2030)
3.4.3 North America Human Immune Globulin Intravenous Revenue by Country (2019-2030)
3.4.4 the United States
3.4.5 Canada
3.5 Europe Human Immune Globulin Intravenous Market Facts & Figures by Country
3.5.1 Europe Human Immune Globulin Intravenous Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Human Immune Globulin Intravenous Sales by Country (2019-2030)
3.5.3 Europe Human Immune Globulin Intravenous Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 UK
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Immune Globulin Intravenous Market Facts & Figures by Country
3.6.1 Asia Pacific Human Immune Globulin Intravenous Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Human Immune Globulin Intravenous Sales by Country (2019-2030)
3.6.3 Asia Pacific Human Immune Globulin Intravenous Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Human Immune Globulin Intravenous Market Facts & Figures by Country
3.7.1 Latin America Human Immune Globulin Intravenous Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Human Immune Globulin Intravenous Sales by Country (2019-2030)
3.7.3 Latin America Human Immune Globulin Intravenous Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Immune Globulin Intravenous Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Immune Globulin Intravenous Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Human Immune Globulin Intravenous Sales by Country (2019-2030)
3.8.3 Middle East and Africa Human Immune Globulin Intravenous Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Immune Globulin Intravenous Sales by Type (2019-2030)
4.1.1 Global Human Immune Globulin Intravenous Sales by Type (2019-2024)
4.1.2 Global Human Immune Globulin Intravenous Sales by Type (2025-2030)
4.1.3 Global Human Immune Globulin Intravenous Sales Market Share by Type (2019-2030)
4.2 Global Human Immune Globulin Intravenous Revenue by Type (2019-2030)
4.2.1 Global Human Immune Globulin Intravenous Revenue by Type (2019-2024)
4.2.2 Global Human Immune Globulin Intravenous Revenue by Type (2025-2030)
4.2.3 Global Human Immune Globulin Intravenous Revenue Market Share by Type (2019-2030)
4.3 Global Human Immune Globulin Intravenous Price by Type (2019-2030)
5 Segment by Application
5.1 Global Human Immune Globulin Intravenous Sales by Application (2019-2030)
5.1.1 Global Human Immune Globulin Intravenous Sales by Application (2019-2024)
5.1.2 Global Human Immune Globulin Intravenous Sales by Application (2025-2030)
5.1.3 Global Human Immune Globulin Intravenous Sales Market Share by Application (2019-2030)
5.2 Global Human Immune Globulin Intravenous Revenue by Application (2019-2030)
5.2.1 Global Human Immune Globulin Intravenous Revenue by Application (2019-2024)
5.2.2 Global Human Immune Globulin Intravenous Revenue by Application (2025-2030)
5.2.3 Global Human Immune Globulin Intravenous Revenue Market Share by Application (2019-2030)
5.3 Global Human Immune Globulin Intravenous Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Takeda
6.1.1 Takeda Corporation Information
6.1.2 Takeda Description and Business Overview
6.1.3 Takeda Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Takeda Human Immune Globulin Intravenous Product Portfolio
6.1.5 Takeda Recent Developments/Updates
6.2 Grifols
6.2.1 Grifols Corporation Information
6.2.2 Grifols Description and Business Overview
6.2.3 Grifols Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Grifols Human Immune Globulin Intravenous Product Portfolio
6.2.5 Grifols Recent Developments/Updates
6.3 CSL
6.3.1 CSL Corporation Information
6.3.2 CSL Description and Business Overview
6.3.3 CSL Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2019-2024)
6.3.4 CSL Human Immune Globulin Intravenous Product Portfolio
6.3.5 CSL Recent Developments/Updates
6.4 Octapharma
6.4.1 Octapharma Corporation Information
6.4.2 Octapharma Description and Business Overview
6.4.3 Octapharma Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Octapharma Human Immune Globulin Intravenous Product Portfolio
6.4.5 Octapharma Recent Developments/Updates
6.5 Biotest
6.5.1 Biotest Corporation Information
6.5.2 Biotest Description and Business Overview
6.5.3 Biotest Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Biotest Human Immune Globulin Intravenous Product Portfolio
6.5.5 Biotest Recent Developments/Updates
6.6 Kedrion
6.6.1 Kedrion Corporation Information
6.6.2 Kedrion Description and Business Overview
6.6.3 Kedrion Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Kedrion Human Immune Globulin Intravenous Product Portfolio
6.6.5 Kedrion Recent Developments/Updates
6.7 Hualan Bio
6.6.1 Hualan Bio Corporation Information
6.6.2 Hualan Bio Description and Business Overview
6.6.3 Hualan Bio Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Hualan Bio Human Immune Globulin Intravenous Product Portfolio
6.7.5 Hualan Bio Recent Developments/Updates
6.8 CNBG
6.8.1 CNBG Corporation Information
6.8.2 CNBG Description and Business Overview
6.8.3 CNBG Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2019-2024)
6.8.4 CNBG Human Immune Globulin Intravenous Product Portfolio
6.8.5 CNBG Recent Developments/Updates
6.9 Shanghai RAAS
6.9.1 Shanghai RAAS Corporation Information
6.9.2 Shanghai RAAS Description and Business Overview
6.9.3 Shanghai RAAS Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Shanghai RAAS Human Immune Globulin Intravenous Product Portfolio
6.9.5 Shanghai RAAS Recent Developments/Updates
6.10 CBPO
6.10.1 CBPO Corporation Information
6.10.2 CBPO Description and Business Overview
6.10.3 CBPO Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2019-2024)
6.10.4 CBPO Human Immune Globulin Intravenous Product Portfolio
6.10.5 CBPO Recent Developments/Updates
6.11 LFB Group
6.11.1 LFB Group Corporation Information
6.11.2 LFB Group Human Immune Globulin Intravenous Description and Business Overview
6.11.3 LFB Group Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2019-2024)
6.11.4 LFB Group Human Immune Globulin Intravenous Product Portfolio
6.11.5 LFB Group Recent Developments/Updates
6.12 BPL
6.12.1 BPL Corporation Information
6.12.2 BPL Human Immune Globulin Intravenous Description and Business Overview
6.12.3 BPL Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2019-2024)
6.12.4 BPL Human Immune Globulin Intravenous Product Portfolio
6.12.5 BPL Recent Developments/Updates
6.13 Sichuan Yuanda Shuyang
6.13.1 Sichuan Yuanda Shuyang Corporation Information
6.13.2 Sichuan Yuanda Shuyang Human Immune Globulin Intravenous Description and Business Overview
6.13.3 Sichuan Yuanda Shuyang Human Immune Globulin Intravenous Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Sichuan Yuanda Shuyang Human Immune Globulin Intravenous Product Portfolio
6.13.5 Sichuan Yuanda Shuyang Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Immune Globulin Intravenous Industry Chain Analysis
7.2 Human Immune Globulin Intravenous Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Immune Globulin Intravenous Production Mode & Process
7.4 Human Immune Globulin Intravenous Sales and Marketing
7.4.1 Human Immune Globulin Intravenous Sales Channels
7.4.2 Human Immune Globulin Intravenous Distributors
7.5 Human Immune Globulin Intravenous Customers
8 Human Immune Globulin Intravenous Market Dynamics
8.1 Human Immune Globulin Intravenous Industry Trends
8.2 Human Immune Globulin Intravenous Market Drivers
8.3 Human Immune Globulin Intravenous Market Challenges
8.4 Human Immune Globulin Intravenous Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
